These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 16410029

  • 1. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs.
    Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T.
    J Control Release; 2006 Mar 10; 111(1-2):56-64. PubMed ID: 16410029
    [Abstract] [Full Text] [Related]

  • 2. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs.
    Willmann S, Thelen K, Becker C, Dressman JB, Lippert J.
    Eur J Pharm Biopharm; 2010 Sep 10; 76(1):83-94. PubMed ID: 20554023
    [Abstract] [Full Text] [Related]

  • 3. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol.
    Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, Toguchi H, Liversidge GG, Higaki K, Kimura T.
    J Control Release; 2008 Aug 25; 130(1):29-37. PubMed ID: 18582979
    [Abstract] [Full Text] [Related]

  • 4. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.
    Miao X, Sun C, Jiang T, Zheng L, Wang T, Wang S.
    J Pharm Pharm Sci; 2011 Aug 25; 14(2):196-214. PubMed ID: 21733409
    [Abstract] [Full Text] [Related]

  • 5. Comparison of three different types of cilostazol-loaded solid dispersion: Physicochemical characterization and pharmacokinetics in rats.
    Mustapha O, Kim KS, Shafique S, Kim DS, Jin SG, Seo YG, Youn YS, Oh KT, Yong CS, Kim JO, Choi HG.
    Colloids Surf B Biointerfaces; 2017 Jun 01; 154():89-95. PubMed ID: 28324691
    [Abstract] [Full Text] [Related]

  • 6. In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration.
    Mahmoud DB, Shukr MH, Bendas ER.
    Int J Pharm; 2014 Dec 10; 476(1-2):60-9. PubMed ID: 25269009
    [Abstract] [Full Text] [Related]

  • 7. Preparation and characterization of microemulsion of cilostazol for enhancement of oral bioavailability.
    Patel SG, Rajput SJ, Groshev A, Sutariya VB.
    Curr Drug Deliv; 2014 Dec 10; 11(4):531-40. PubMed ID: 24274587
    [Abstract] [Full Text] [Related]

  • 8. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats.
    Xia D, Cui F, Piao H, Cun D, Piao H, Jiang Y, Ouyang M, Quan P.
    Pharm Res; 2010 Sep 10; 27(9):1965-76. PubMed ID: 20585842
    [Abstract] [Full Text] [Related]

  • 9. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate.
    Seo JH, Park JB, Choi WK, Park S, Sung YJ, Oh E, Bae SK.
    Drug Des Devel Ther; 2015 Sep 10; 9():3961-8. PubMed ID: 26251575
    [Abstract] [Full Text] [Related]

  • 10. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, Chen C, Thompson K, Higgins R, Batra U, Shelukar S, Kwei G, Storey D.
    Int J Pharm; 2004 Nov 05; 285(1-2):135-46. PubMed ID: 15488686
    [Abstract] [Full Text] [Related]

  • 11. Improvement of dissolution and absorption properties of poorly water-soluble drug by preparing spray-dried powders with alpha-glucosyl hesperidin.
    Uchiyama H, Tozuka Y, Imono M, Takeuchi H.
    Int J Pharm; 2010 Jun 15; 392(1-2):101-6. PubMed ID: 20307634
    [Abstract] [Full Text] [Related]

  • 12. In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative.
    Xu D, Ni R, Sun W, Li LC, Mao S.
    Drug Dev Ind Pharm; 2015 Apr 15; 41(4):552-9. PubMed ID: 24495272
    [Abstract] [Full Text] [Related]

  • 13. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.
    Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, Bergström CA.
    Mol Pharm; 2010 Oct 04; 7(5):1419-30. PubMed ID: 20507160
    [Abstract] [Full Text] [Related]

  • 14. Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state.
    Ma Q, Sun H, Che E, Zheng X, Jiang T, Sun C, Wang S.
    Int J Pharm; 2013 Jan 30; 441(1-2):75-81. PubMed ID: 23266761
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles.
    Wong SM, Kellaway IW, Murdan S.
    Int J Pharm; 2006 Jul 06; 317(1):61-8. PubMed ID: 16647232
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
    Nekkanti V, Pillai R, Venkateshwarlu V, Harisudhan T.
    Pharm Dev Technol; 2009 Jul 06; 14(3):290-8. PubMed ID: 19235553
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.
    Woo SK, Kang WK, Kwon KI.
    Clin Pharmacol Ther; 2002 Apr 06; 71(4):246-52. PubMed ID: 11956507
    [Abstract] [Full Text] [Related]

  • 19. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants.
    Shin KH, Yoon G, Yoon IS, Park JW.
    J Pharm Pharmacol; 2014 Jul 06; 66(7):961-74. PubMed ID: 24697278
    [Abstract] [Full Text] [Related]

  • 20. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs.
    Yan-yu X, Yun-mei S, Zhi-peng C, Qi-neng P.
    Int J Pharm; 2006 Aug 17; 319(1-2):162-8. PubMed ID: 16687221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.